Gildan® is the leading activewear brand in the screenprint market in the U.S. and Canada. The brand is continuing to grow in Europe, Mexico and the Asia-Pacific region. The Company sells T-shirts, sport shirts and fleece as undecorated “blanks”, which are subsequently decorated by screenprinters with designs and logos. The Company is also one of the world’s largest suppliers of branded and private label athletic, casual and dress socks sold to a broad spectrum of retailers in the U.S. Gildan markets its sock products under a diversified portfolio of company-owned brands, including Gold Toe®, PowerSox®, SilverToe®, Auro®, All Pro®, GT®, and the Gildan® brand. The Company is also the exclusive U.S. sock licensee for the Under Armour® and New Balance® brands. In addition to socks, the Company is increasingly becoming a significant supplier of underwear and undecorated activewear products in the retail channel.
Consumer Cyclical Sector WrapFox Business -
20 hours ago The S&P 500 lost 0.4% while the Consumer Cyclical sector (XLY) showed little movement during trading today. As a proxy for the sector, the ETF tracked closer to the overall market today than over the past month.
Why Gildan Activewear's Earnings May Not Be So HotDailyFinance -
May 11, 2012 By Seth Jayson, The Motley Fool Although business headlines still tout earnings numbers, many investors have moved past net earnings as a measure of a company's economic output.
Gildan Announces Completion of Acquisition of AnvilMarketWatch (press release) -
May 9, 2012 MONTREAL, QUEBEC, May 09, 2012 (MARKETWIRE via COMTEX) -- Gildan Activewear Inc. (TOR:CA:GIL) (NYSE:GIL) today announced that it has completed the acquisition of Anvil Holdings, Inc. (Anvil), effective May 9, 2012.
Gildan Activewear Beats Estimates but Has a Big Earnings DropDailyFinance -
May 7, 2012 By Seth Jayson, The Motley Fool Gildan Activewear (NYS: GIL) reported earnings on May 3. Here are the numbers you need to know. For the quarter ended April 1 (Q2), Gildan Activewear missed estimates on revenues and beat expectations on earnings per ...
Analyst Insights: Novavax, Abbott, Gildan, PVH, Rovi May 4thWall St. Cheat Sheet -
May 4, 2012 By Derek Hoffman Abbott Laboratories (NYSE:ABT): RBC Capital expects an FDA panel evaluating Pfizer's (NYSE:PFE) rheumatoid arthritis drug to recommend that the agency approve the treatment, which will compete with Abbott's (NYSE:ABT) Humira.